Tradestie Institutional Equity Comparison Engine

IART vs ARTC โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-20 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

IART Overall Edge

IART Captures Institutional Edge (3โ€“1 Pillars ยท 7โ€“3 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Integra LifeSciences Holdings (IART) driven by superior Valuation, Growth & Margin, Options & Structure while ARTC counters with relative strength in Momentum & Technical. Fundamentally, IART trades at 5.6x Forward P/E with 9.9% operating margin (+2.3% YoY revenue) versus ARTC at N/M Forward P/E and N/A operating margin (N/A YoY). In options structure, IART sits in BREAKDOWN (16th %ile IV; Dealer Gamma Walls on Pro) against ARTC sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro).

Valuation Winner IART
IART 5.6x vs ARTC N/M Fwd P/E
Growth & Margin Winner IART
Op Margin 9.9% vs N/A ยท YoY +2.3% vs N/A
Momentum & Technical Winner ARTC
1Y +18.8% vs +2.2% ยท 52W Pos 39% vs 100%
Options & Structure Winner IART
BREAKDOWN (16th %ile IV) vs UNCLASSIFIED (N/A IV)
IART NASDAQ
Integra LifeSciences Holdings
Surgical & Medical Instruments & Apparatus
$13.25
-2.21% 1D
Market Cap $1.1B
1M Return +7.51%
1Y Return +18.83%
Forward P/E 5.6x
Unified AI Score
45.5 / 100 HOLD
Tech 43.0 Fund 53.0 Flow 68.0 Mom 50.0
ARTC US Equity
ARTC
Institutional Equity
$10.05
+0.2% 1D
Market Cap N/A
1M Return +0.3%
1Y Return +2.24%
Forward P/E N/M
Unified AI Score
62.3 / 100 BUY
Tech 67.0 Fund 57.0 Flow 50.0 Mom 50.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: IART +18.83% ARTC +2.24% Spread: +16.83 pp (IART Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
IART TTM Op. Margin: 9.9% ARTC TTM Op. Margin: N/A
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on IART vs ARTC. Trailing 12-month operating profitability (IART 9.9% vs ARTC N/A) and valuation multiples (IART 5.6x vs ARTC N/M Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: IART (7) vs ARTC (3)
Institutional Metric IART ARTC Criterion Row Winner
Market Capitalization Scale $1.1B N/A Larger Scale IART
Trailing P/E Ratio Valuation 79.7x N/M Lower Multiple IART
Forward P/E Ratio Valuation 5.6x N/M Lower Multiple IART
Revenue Growth (YoY) Growth +2.3% N/A Higher Growth IART
Operating Margin (TTM) Profitability 9.9% N/A Higher Margin IART
Net Profit Margin Profitability 0.8% N/A Higher Margin IART
Return on Equity (ROE) Capital Efficiency 1.2% N/A Higher ROE IART
52-Week Range Position Momentum 39% ($9โ€“$20) 100% ($10โ€“$10) Stronger Trend ARTC
Beta / 30D Volatility Risk Regime 1.54ฮฒ ยท 60% Vol -0.02ฮฒ ยท 2% Vol Lower Realized Risk ARTC
Unified Institutional Score Composite Signal 45.5 / 100 (HOLD) 62.3 / 100 (BUY) Higher Composite ARTC

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full IART vs ARTC Buy Guide
IART BREAKDOWN
103d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 16th %ile
IV Regime Compressed (<25th %ile)
Live IART Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
ARTC UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile N/A
IV Regime Unclassified
Live ARTC Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither IART nor ARTC registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.